EICHORPublic-registry site landscape for NCT05878938, “A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)”, a Haemophilia A study sponsored by Novo Nordisk A/S. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05878938 (registry record) |
| Study title | A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) |
| Official title | Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis |
| Sponsor | Novo Nordisk A/S |
| Condition(s) | Haemophilia A; Haemophilia A With Inhibitors |
| Phase | PHASE3 |
| Listed sites | 36 |
| Intervention(s) | NNC0365-3769 (Mim8) PPX |
| Site countries | United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, South Africa, South Korea, Spain, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05878938.
Eichor generates a preliminary site-risk snapshot for NCT05878938 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
